Bone graft

1. Page 1
Bone Void Fillers : Bone
And Bone substitutes
Dr Sitanshu

2. Page 2
Introduction
•2nd most common graft
•Gold standard – autogenous cancellous
bone
•Drawbacks – Morbidity
Availability
Operative time

3. Page 3
•Allograft – immune response
disease transfer
impaired osteoconductivity
reduced mechanical property
cost

4. Page 4
•1
st
phase – 4 weeks – mainly from cells of
graft
•2
nd
phase – host cells (endosteal cells,
marrow cells, osteocytes)

5. Page 5
Role of cancellous bone
•Scaffold where cells interact
•Nutrition
•Hematopoiesis, Myelogenesis, Platelet
formation
•Source of pluripotent osteoprogenitor stem
cell
•Local growth factors for differentiation
•Same strength of cortical bone by 6-12
months

6. Page 6
General characteristics of successful
bone graft
Osteogenesis
Osteoinduction
Osteoconduction
Good handling characteristic
Non toxic
Biomechanical property similar to cancellous
bone

7. Page 7
Osteogenesis
Process of bone formation through cellular
osteoblastic activity which depends on the
presence of osteoprogenitor stem cells.

8. Page 8
Osteoinduction
Biologically mediated recruitment and
differentiation of cell types essential for
bone formation.

9. Page 9
Osteoconduction
Apposition of growing bone to three
dimensional surface of a suitable scaffold
provided by the graft.

10. Page 10
Potential use of natural and synthetic
grafts
•Fusion – cervical fusion
lumbar onlay graft
lumbar interbody fusion
arthrodesis
•Bone void filler – collapsed vertebral body
autograft donor site
repair
bony defects

11. Page 11
Autograft - Pros
•Osteogenic
•Osteoinductive
•Osteoconductive
•No disease transmission
•No host rejection

12. Page 12
Autograft - Con
•Viability is compromised
•Quality is not constant
•Second fascial incision

13. Page 13
Minor complications
Superficial infection
Seroma
Hematoma
Temporary sensory loss
Transient pain

14. Page 14
Major complications
•Infection
•Prolonged wound
drainage
•Hernia
•Deep hematoma
•Need for reoperation
•Pain > 6 months
•Profound sensory
loss
•Heterotopic bone
formation
•Vascular injury
•Neurologic injury
•Scars
•Subluxation
•Gait disturbance
•SI destabilization
•Enterocutaneous
fistula
•Pelvic fracture

15. Page 15
•3cm – distance from donor site and ASIS /
PSIS
•3cm – maximum distance from dorsal
ilium

16. Page 16
Factors which can’t be avoided
•Increased operative time
•Blood loss
•Donor site – pain
•Cosmetic defect

17. Page 17
Sites
•Iliac crest (Anterior or posterior iliac crest)
•Greater trochanter
•Gerdy's tubercle
•Distal part of the radius
•Distal part of the tibia

18. Page 18
•Autogenous cancellous bone graft is an excellent choice
for nonunions with <5 to 6 cm of bone loss and that
do not require structural integrity from the graft. It can
also be used to fill bone cysts or bone voids after
reduction of depressed articular surfaces such as in a
tibial plateau fracture. Stable internal or external
fixation is also required, to provide the optimum
environment for graft consolidation and successful
fracture-healing.

19. Page 19
Autogenous cortical graft
•Fibula
•Ribs
•Iliac crest

20. Page 20
•With or without vascular pedicle
•Osteoconduction + Osteogenesis
•Non vascularized grafts become weaker in
6 weeks – resorption, revascularization
•Vascularized – stronger – remodelling
similar to normal bone
•But by 6-12 months – no difference
•Fixation required

21. Page 21
•Advantage
•Defects > 5-6cm
•Immediate structural
support
•Disadvantage
•Subjective sense of
weakness and
instability
•Big toe weakness
•Need for reoperation
at donor site

22. Page 22
Osteoconductive matrices
•No osteogenic or osteoinductive property
•Greater source availability
•Elimination of second operative site
•Tricalcium phosphate (alpha, beta)
•Hydroxyapatite
•Injectable calcium phosphate cement

23. Page 23
Graft Material Osteogenesis Osteoinduction Osteoconduction
Autograft 2* 2 2
Allograft 0 1 2
Xenograft 0 0 2
α-TCP 0 0 1
β-TCP (porous) 0 0 2
Hydroxyapatite 0 0 1
Injectable calcium
phosphate cement
(e.g., Norian SRS†) 0 0 1
BMA 3 2 0
β-TCP plus BMA 3 2 2
DBM 0 2 1
Collagen 0 0 2
BMP 0 3 0
Hyaluronic acid 0 0 0
Bioactive glasses 0 0 1 Degradable
polymer 0 0 1
Porous metals 0 0 1

24. Page 24
Allograft
•Surge in popularity – increased availability
donor screening and
tissue processing for safety
new forms has
increased versatility

25. Page 25
•Machine tooling to shape structural
allograft
•Reduction of procurement morbidity
•Potential for immediate structural support
•Reasonable success (60-90%)

26. Page 26
Allograft - ConA
•Results inferior to autograft
•Vary in initial bone quality
•Expensive
•Disease transmission
•Immunogenic reaction

27. Page 27
•Processing – its disadvantage
•Slower resorption
•Not completely replaced by new bone
•Reduced structural integrity
•Poor results in lumbar fusion

28. Page 28
•Donor to donor variation
•Low grade inflammatory reaction

29. Page 29
•Animal studies – correlation between
histocompatibility difference and allograft
failure
•Reaction specific to donor antigen
•CD8+ reaction

30. Page 30
•Fresh frozen
•Retain BMP
•Strong
•Better incorporation
•Immunogenic
•Disease transmission
•Freeze dried
•No BMP
•Weak
•Weaker
•Least immunogenic
•No documented
disease transmission

31. Page 31
Demineralized bone matrix
•Allograft bone that has had the inorganic
mineral removed, leaving behind the
organic collagen matrix
•More osteoinductive properties
•DBM + glycerol carrier – commonly used
•Available data – more as bone graft
extender, not substitute

32. Page 32
• Revascularizes quickly

33. Page 33
Factors affecting DBM product
•Processing
•Time of demineralization
•Final particle size
•Terminal sterilization
•Carrier
•Donor viability

34. Page 34
Carrier for DBM
•Glycerol
•Thermogelling chitosan
•Hyaluronic acid
•Recombinant BMP
•Albumin
•Carboxymethyl cellulose

35. Page 35
Disadvantage
•Difficulty in handling
•Tendency to migrate from graft site
•Lack of stability
•Transmit disease

36. Page 36
Xenograft
•From animals
•Impractical for clinical use on a wide scale
•Removal of protein and fat – processing
•Removes osteoinductive proteins
•Kiel bone, Oswestry, Bio Oss

37. Page 37
Ceramics
•Stable compounds of metals with oxygen
or other anions
•Non injectable ceramics – according to
resorbing power
•Injectable ceramics

38. Page 38
Non injectable ceramics
•Osteoconductive
•Hydroxyapatite, Tricalcium phosphate,
Calcium sulphate dihydrate
•High quality synthetic material with no
biologic hazards

39. Page 39
•Alternative or as an addition to either
cancellous autograft or allograft or as a
cancellous bone void filler or bone graft
extender or in sites where compression is
the dominant mode of mechanical loading
•Safe and effective substitute for iliac graft
autograft
•Cost

40. Page 40

41. Page 41
Rapidly resorbing ceramics
•Tricalcium phosphate (alpha 1200
degrees, beta at 800 degrees) – 39% Ca,
20% P
•Calcium sulfate

42. Page 42
•Calcium phosphate – calcium phosphate
rich microenvironments that stimulate
osteoclastic resorption and then
osteoblastic new bone formation, resulting
in new bone formation
•Pore size - less porous formulations
resorb before complete bone ingrowth

43. Page 43
•Calcium sulfate - Osteoconductive but its
rapid resorption rate creates doubt about
its ability to maintain a three-dimensional
framework to support Osteogenesis

44. Page 44
Intermediate resorbing ceramic
•Beta tricalcium phosphate - In the process
of being resorbed, it can enrich the local
environment with osteogenic substrates
that, in turn, can be used by activated
osteoblasts
•Broad range of pore size (<1µm to
1000µm)
•Sponge-like interconnected microporosity
endowed with excellent wicking and
hydrophilic properties

45. Page 45
Slow resorbing ceramic
•Hydroxyapatite
•Bone incorporation – pore size and pore
interconnectivity
•Drawback - slow resorption, brittle

46. Page 46
Injectable ceramics
•Calcium phosphate cement - paste of
inorganic calcium and phosphate that
hardens in situ with a low exothermic
temperature
•Slowly transforms into bone over 3 to 4
years
•Adjunct to fixation in both femoral neck
and intertrochanteric hip fractures

47. Page 47
•Drawbacks – 1. slow resorption
2. low porosity
3. high cost
4. extravasation
5. intra articular extension
6. increased washout
7. low shear resistance

48. Page 48
Collagen
•Animal-derived collagen with synthetic
calcium phosphate
•Putty-like consistency
•Can be used as bone graft extenders to
increase the volume of bone graft into a
defect when a sufficient volume of
autograft is not readily available

49. Page 49
Non biologic Osteoconductive
substrates
1. absolute control of the final structure
2. no immunogenicity
3. excellent biocompatibility
Degradable polymers - polylactides
Bioactive glasses
Porous metals - tantalum

50. Page 50

51. Page 51
Composite graft
•Any combination of materials that includes
both an osteoconductive matrix and an
osteogenic or osteoinductive material
1.Bone marrow aspirate
2.Osteoblastic progenitor stem cell
3.Blood
4.Platelet rich plasma
5.Growth factors

52. Page 52
Bone marrow aspirate
background
•Osteoblast progenitor cells – 1.periosteum
of long bones 2.the peritrabecular
connective tissue 3.the bone marrow
•All the critical cellular components that
contribute to bone growth present
•Fibroblast, undifferentiated cells
•Animal research suggests that precursor
cells in bone marrow proliferate and
differentiate after transplantation

53. Page 53
•Availability and the relative safety of its
harvest
•Harvested by aspiration from patients, with
limited dilution by peripheral blood
•Concentration
•Culture

54. Page 54
Bone composite
•Used successfully to stimulate healing in
tibial fractures
• Osteogenic potential was maintained as
the cells were expanded in culture
•Facilitated greater bone formation and
fusion success rates
• Xenograft bone and other bone
substitutes could be rendered osteogenic

55. Page 55
Synthetic composite
•Addition of BMA was essential for
tricalcium phosphate and hydroxyapatite
to achieve results comparable to those
obtained with cancellous bone at 24
weeks
•β-TCP/BMA composite may be superior
even to autograft, which suffers from
anoxic cell death in the center of the graft
because of the absence of vascularization

56. Page 56

57. Page 57
BMP and synthetic composite
•BMP 2, BMP 7 (rhOP 1)
•Carrier to maintain optimum regional
concentration
•Hydroxyapatite
•DBM
•Hyaluronic acid
•Collagen